michael a narachi  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in michael a narachi dir president and chief executive officer at orexigen therapeutics inc view full profile are you michael a narachi claim your profile   sign up for equilar atlas and view michael a narachis full profile with equilar atlas you can identify corporate executives in michael a narachis network and community follow changes in michael a narachis employment and moneyinmotion connect with michael a narachi through your network of contacts michael a narachis executive work history current dir president and chief executive officer orexigen therapeutics inc board member ultragenyx pharmaceutical inc past to view michael a narachis complete executive work history sign up now education bs university of california  davis mba university of california  los angeles age      michael a narachis biography michael a narachi has served as our president and chief executive officer and a member of our board of directors since march  previously mr narachi served as chairman chief executive officer and president of ren pharmaceuticals inc a private biotechnology company from november  to march  from august  to january  mr narachi served as chairman of the board of directors of naryx pharma inc a private pharmaceutical company in  mr narachi retired as an officer and vice president of amgen inc a leading therapeutics company where he served as general manager of amgens anemia business from  to  m  read more michael a narachi has served as our president and chief executive officer and a member of our board of directors since march  previously mr narachi served as chairman chief executive officer and president of ren pharmaceuticals inc a private biotechnology company from november  to march  from august  to january  mr narachi served as chairman of the board of directors of naryx pharma inc a private pharmaceutical company in  mr narachi retired as an officer and vice president of amgen inc a leading therapeutics company where he served as general manager of amgens anemia business from  to  mr narachi joined amgen in  and held various positions throughout the organization including product development team leader for neupogen� director of clinical operations in thousand oaks ca and cambridge uk vice president of development and representative director for amgen japan head of corporate strategic planning chief operations officer of amgen biopharma and vice president licensing and business development he currently serves as a member of the board of directors of ultragenyx pharmaceutical inc a publicly traded biopharmaceutical company and previously served as the chairman of the board of directors of celladon corporation a publicly traded biotechnology company from  until  and as a member of the board of directors of amag pharmaceuticals inc from  until  mr narachi received a bs in biology and an ma degree in biology and genetics from the university of california at davis he received an mba from the anderson graduate school of management at university of california los angeles key attributes experience and skills and the benefit to the board of directors include mr narachi brings to our board of directors valuable business leadership and management experience and knowledge of our company and the biotechnology industry mr narachis services as our president and chief executive officer provide a critical link between management and the board of directors and ensures that the board takes into consideration managements perspectives on the business this critical link also helps the board to perform its oversight function source orexigen therapeutics inc on    sign up for equilar atlas and view michael a narachis full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like michael a narachi more specifically youll be able to identify corporate executives in michael a narachis network and community follow changes in michael a narachis employment and moneyinmotion connect with michael a narachi through your network of conections view full profile   search for over  executive profiles bio example michael a narachi michael a narachis connections  sign up now to view michael a narachis  connections » eckard weber chairman of the board ocera therapeutics inc paul j hastings chairman of the board chief executive officer and president oncomed pharmaceuticals inc louis c bock board member orexigen therapeutics inc steven j mento dir president chief executive officer and acting principal financial officer conatus pharmaceuticals inc brian h dovey board member orexigen therapeutics inc kleanthis g xanthopoulos board member apricus biosciences inc stuart a arbuckle executive vice president and chief commercial officer vertex pharmaceuticals incorporated luigi lenaz lead director spectrum pharmaceuticals inc clay b siegall president chief executive officer and chairman of the board seattle genetics inc david m stout board member jabil inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla david j oconnor president and ceo the madison square garden company carl g annessa evp and coo hornbeck offshore services inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   michael narachi chairman celladon timesjavascript is disabled market profiles login sign up login sign up   edit person michael narachi chairman at celladon location san diego ca add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop michael narachi chairman at celladon location san diego ca add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop michael currently serves as president and chief executive officer of orexigen therapeutics inc michael has  years of biotechnology and pharmaceutical experience across a broad range of functions including clinical development commercialization strategic business development and planning prior to joining orexigen michael served as chairman chief executive officer and president of ren pharmaceuticals inc a private biotechnology company and executive chairman of the board of naryx pharma inc a private pharmaceutical company in  narachi retired as an officer and vice president and general manager of amgen’s anemia business throughout his  years at amgen michael held various positions including product development team leader for neupogen director of clinical operations in thousand oaks calif and cambridge uk vice president of development and representative director for amgen japan head of corporate strategic planning chief operations officer of amgen biopharma and vice president licensing and business development he is also chairman of amag pharmaceuticals inc and a member of the board of directors at the biotechnology industry organization bio and the pharmaceutical research and manufacturers of america phrma  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags na topics of influence web site na careers achievements investments related people edit view all michael narachicareer  oct celladon chairman  orexigen therapeutics president and chief executive officer ren pharmaceuticals inc chairman chief executive officer and president competencies edit view all michael narachieducation  ucla anderson school of management  university of california  university of california edit michael narachiachievements and recognitions add milestone no milestones has been recorded for michael narachi edit michael narachilinks add link no links has been recorded for michael narachi michael narachiinvestmentsacquisitions no investments has been recorded for michael narachi michael narachiinvestments representing others no investment reps has been recorded for michael narachi michael narachirelated people colleagues at celladon patrick yang board of director mar peter honig board of director mar graham cooper board of director sep gregg alton board of director sep view all michael narachirecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies michael narachi orexigen therapeutics inc profile  biography  bloomberg feedback michael mike narachi presidentceo orexigen therapeutics inc career history presidentceo orexigen therapeutics inc present presidentceointerim cfo orexigen therapeutics inc  presidentceo orexigen therapeutics inc  chairmanpresidentceo ren pharmaceuticals inc  chairman naryx pharma inc  vp  cooanemia business amgen inc unknown chairman sinuspharma inc unknown chairman sinuspharma inc unknown chairman sinuspharma inc unknown vpdevrepresentative dir amgen japan former amgen inc former headcorporate strategic amgen inc former vplicensing  business dev amgen inc former show more website wwworexigencom corporate information address  northtorrey pines court suite  la jolla ca  united states phone  fax  web url wwworexigencom from the web personal information education university of california masters degree  university of california bachelors degree biology anderson university graduate school of management mba show more memberships board memberships biotechnology innovation organization board member present ultragenyx pharmaceutical inc board member present pharmaceutical research  manufacturers of america board member present orexigen therapeutics inc board member present celladon corp chairman  biotech industry org board member unknown amag pharmaceuticals inc chairman unknown ren pharmaceuticals inc miscellaneous  naryx pharma inc chairman  advanced magnetics inc board member  amag pharmaceuticals inc board member unknown sinuspharma inc chairman unknown show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data michael narachi search search home newsnewspharmaceutical newsbiotechnology newsgenerics newsbiosimilars newsmergers  acquisitionsregulationworld newstop news stories people with chronic kidney disease should be offered statins says nicepharmaceuticalwho prequalification for generic sovaldigenerics in depthin depthanalysisspecial reportinterviewin conversation with expert viewfrom our correspondentin the boardroomtop in depth stories after  years of failure what can pharma offer alzheimers patientspharmaceuticalpatient centricity making clinical trials more effective by keeping focus on the patientpharmaceutical conference roundupconference roundupaaic eular easl asco aacr annual meeting ectrims top conference roundup stories people with chronic kidney disease should be offered statins says nicepharmaceuticalwho prequalification for generic sovaldigenerics focus onfocus onbrexitfdapricingemarussian markettrump administrationtop focus on stories inquiry asks how to stimulate uk life sciences innovationpharmaceuticalbrexit and longerterm sector trends could boost uk pharma mainvestmentbiotechnology events companies reports michael narachi orexigen therapeutics president and chief executive officer president and chief executive officer orexigen therapeutics michael narachi has served as president and chief executive officer and a member of our board of directors since march  previously mr narachi served as chairman chief executive officer and president of ren pharmaceuticals inc a private biotechnology company from november  to march  from august  to january  mr narachi served as chairman of the board of directors of naryx pharma inc a private pharmaceutical company in  mr narachi retired as an officer and vice president of amgen inc a leading therapeutics company where he served as general manager of amgens anemia business from  to  mr narachi joined amgen in  and held various positions throughout the organization including product development team leader for neupogen® director of clinical operations in thousand oaks ca and cambridge uk vice president of development and representative director for amgen japan head of corporate strategic planning chief operations officer of amgen biopharma and vice president licensing and business development he currently serves on the board of directors of amag pharmaceuticals inc a publicly traded pharmaceutical company mr narachi received a bs in biology and an ma degree in biology and genetics from the university of california at davis he received an mba from the anderson graduate school of management at university of california los angeles mr narachi also currently serves as a member of the board of directors of phrma the pharmaceutical research and manufacturers of america bio the biotechnology industry organization and amag pharmaceuticals inc a publicly traded pharmaceutical company related pharma letter news orexigen files for canadian approval of weight loss drugthe obesity epidemic what is pharma doingorexigen targets growing obesity problem in spain more pharma letter news related news from the web monday sector leaders biotechnology music  electronics stores more related news orexigen therapeuticsus biopharma company orexigen therapeutics nasdaq orex is a biopharmaceutical company focused on the treatment of obesity editors picks most read top  stories of in alzheimers the juggernaut is changing course says taurx chief execepigenetic biomarkers set to make “a huge difference in human health” says cambridge epigenetix’s tiffany morrisemachmp recommends eight new drugs for approval including five orphansbrexit and longerterm sector trends could boost uk pharma mainvestmentsuccess of chinese pilot a step forward in the ‘globalization of drug regulation’top  stories of pfizer’s biosimilar shows similarity to avastinnice recommends treatment with daxas for copdbiogen lures novartis executive to its teamchiesi cleared to market copd drug in europelonza and sanofi to build new multidisciplinary biomanufacturing facility in switzerland company spotlightzymeworkszymeworks is a clinicalstage biopharmaceutical company dedicated to the discovery development and commercialization of nextgeneration multifunctional biotherapeutics initially focused on the treatment of cancer tweets sign up for our daily newsletter our latest news direct to your inbox newsletter back to top ultragenyx appoints michael narachi to board of directors nasdaqrare facebook google linkedin twitter email rss feb   previous release  next release pdf add to briefcase file is in briefcase ultragenyx appoints michael narachi to board of directors novato calif feb   globe newswire  ultragenyx pharmaceutical inc nasdaqrare a biopharmaceutical company focused on the development of novel products for rare and ultrarare diseases today announced the appointment of michael narachi to the companys board of directors effective february   mr narachi president and chief executive officer and a director of orexigen therapeutics inc will serve as an independent director to ultragenyx on behalf of the board of directors and executive team at ultragenyx i am pleased to welcome mike to the board with his proven track record leading young biotech companies mikes broad expertise and diverse experience will be of tremendous value to ultragenyx as it enters the next phase of its development said emil d kakkis md phd chief executive officer of ultragenyx i am excited to join ultragenyx at a critical time of the companys growth and to be a part of the continued progress of advancing drug development to addressing severe and potentially lifethreatening diseases said mr narachi i look forward to working closely with the board and the ultragenyx team to bring therapies to patients affected by these rare and ultrarare diseases mr narachi currently serves as president and chief executive officer and a director of orexigen therapeutics inc a position he has held since march  previously mr narachi served as chairman chief executive officer and president of ren pharmaceuticals inc a private biotechnology company from november  to march  from august  to january  mr narachi served as chairman of the board of directors of naryx pharma inc a private pharmaceutical company mr narachi joined amgen in  and held various senior positions throughout the organization over a  year career including vice president of development and representative director for amgen japan head of corporate strategic planning chief operations officer of amgen biopharma and vice president licensing and business development  he served as general manager of amgens anemia business from  to  until his retirement in  as an officer and vice president of amgen inc he currently serves as the chairman of the board of directors of celladon corporation a publicly traded biotechnology company mr narachi received a bs in biology and an ma degree in biology and genetics from the university of california at davis he received an mba from the anderson graduate school of management at university of california los angelesabout ultragenyx ultragenyx is a clinicalstage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultrarare diseases with a focus on serious debilitating genetic diseases founded in  the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high the biology for treatment is clear and for which there are no approved therapies the company is led by a management team experienced in the development and commercialization of rare disease therapeutics ultragenyxs strategy is predicated upon time and costefficient drug development with the goal of delivering safe and effective therapies to patients with the utmost urgency for more information on ultragenyx please visit the companys website at wwwultragenyxcomcontact ultragenyx pharmaceutical inc  for media bee nguyen for investors robert anstey compensation information for michael a narachi  president chief executive officer and member of the board of directors of orexigen therapeutics inc  salarycom enterprise small business personal contact us log in salaries jobs education advice michael a narachi executive compensation as president chief executive officer and member of the board of directors at orexigen therapeutics inc michael a narachi made  in total compensation of this total  was received as a salary  was received as a bonus  was received in stock options  was awarded as stock and  came from other types of compensation this information is according to proxy statements filed for the  fiscal year enter an executive or company name new search go the chart on this page features a breakdown of the total annual pay for michael a narachi  president chief executive officer and member of the board of directors at orexigen therapeutics inc as reported in their proxy statements total cash compensation information is comprised of yearly base pay and bonuses orexigen therapeutics inc income statements for executive base pay and bonus are filed yearly with the sec in the edgar filing system orexigen therapeutics inc annual reports of executive compensation and pay are most commonly found in the def a documents total equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year other compensation covers all compensationlike awards that dont fit in any of these other standard categories numbers reported do not include change in pension value and nonqualified deferred compensation earnings other executives at this company thomas lynch thomas cannell dvm michael a narachi base pay bonus  incentive comp total cash compensation stock award value option award value total equity total other total compensation browse executives by first name a b c d e f g h i j k l m n o p q r s t u v w x y z browse companies by company name a b c d e f g h i j k l m n o p q r s t u v w x y z  this report is not for commercial use thorough reviews have been conducted to assure this data accurately reflects disclosures however for a complete and definitive understanding of the pay practices of any company users should refer directly to the actual complete proxy statement use of data  disclaimer the information shown here is a reporting of information included in the companys proxy statement the proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information for those interested in conducting a detailed compensation analysis we recommend that you review the entire proxy statement you may retrieve the full proxy statement by going to the securities and exchange commission sec website at wwwsecgov and entering the companys name and then looking in the first column for an entry of form def a or any similar code you may also find the annual proxy statement by going directly to the companys website what is a proxy statement a proxy statement or proxy is a form that every publicly traded us company is required to file with the us securities  exchange commission sec within  days after the end of its fiscal year the proxy must be sent to every shareholder in advance of the companys annual shareholders meeting all proxy statements are public filings made available to the general public by the sec the proxy statements main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting including decisions such as electing directors ratifying the selection of auditors and other shareholderrelated decisions including shareholderinitiated initiatives also proxies must disclose specific detailed information regarding the pay practices for certain executives       privacy policy terms of use about us contact us  salarycom all rights reserved us salaries canadian salaries purchase a salary report salaries by category salaries by income salaries by industry popular salaries negotiation tips benefits calculator search job openings job openings by state job openings by category education by career education by level education by major cost of living calculator orex michael a narachi insider trades for orexigen therapeutics inc bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close orexigen therapeutics inc nasdaq orex go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus orexigen therapeutics inc after hours  quotes are delayed by  min jul    pm orex quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   insider activity individual michael a narachi mr michael a narachi is on the board of directors at ultragenyx pharmaceutical inc pharmaceutical research  manufacturers of america orexigen therapeutics inc and biotechnology industry organization mr narachi was previously employed as chairman by celladon corp chairman president  chief executive officer by ren pharmaceuticals inc executive chairman by naryx pharma inc and executive vice president by amgen inc he also served on the board at amag pharmaceuticals inc he received his undergraduate degree from the university of california davis a graduate degree from the university of california davis and an mba from ucla anderson school of management transactions date shares transaction value     award at  per share      award at  per share      award at  per share      award at  per share      award at  per share      acquisition at  per share      award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr michael a narachi president chief executive officer  director dr thomas r cannell chief operating officer  executive vice president mr jason keyes chief financial officer  senior vice president ms beth eastland vice presidentsales mr stephen a moglia principal accounting officer mr thomas p lynch secretary executive vp  general counsel dr peter d flynn svp headdevelopment regulatory affairs  safety mr patrick j mahaffy chairman ms deborah a jorn independent director ms lota s zoth independent director mr louis c bock independent director mr brian h dovey independent director mr david j endicott independent director dr peter k honig independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthis social network ranks as the worst for young people’s mental health it’s not facebook pmove over breathalyzers ‘textalyzers’ could be used on drivers’ phones pthis is the worst mistake people make at work pcities to move to if you want to work in tech — not including san francisco pwhat donald trump’s battle of wills with jeff sessions teaches you about a difficult boss pwatch out for these surprise charges at the er pthe open road or the open skies millennials choose the former phow an online wedding registry in my name appeared out of thin air pdon’t have a college degree these are the industries with the bestpaid jobs pthe highest paid athletes in the world in one chart phow to teach your kids to be better with money than you are pbacktoschool shopping goes mainstream with deals on eyewear fitness apparel and kitchen appliances psamsung posts record profits on back of strong galaxy s sales pthe dark side of cruises pfor transgender americans workplace discrimination isn’t limited to the military pscaramucci on washington back stabbers ‘i’m more of a frontstabbing person’ pfacebook keeps warning about growth but growth doesn’t stop pfacebook heads toward  billion market cap after earnings pfoxconn pledges to build  billion stateoftheart electronics plant in wisconsin pgraham says trump is showing weakness in unilateral public spat with sessions loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  michael narachi  orexigen therapeutics  inc  zoominfocom